The highest estimate is 46.00. From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALMS.BOATS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
The current price of ALMS.BOATS is $23.44 USD — it has increased by +3.17% in the past 24 hours. Watch Alumis stock price performance more closely on the chart.
What is Alumis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alumis stocks are traded under the ticker ALMS.BOATS.
What is Alumis market cap?▼
Today Alumis has the market capitalization of 2.28B
When is the next Alumis earnings date?▼
Alumis is going to release the next earnings report on May 20, 2026.
What were Alumis earnings last quarter?▼
ALMS.BOATS earnings for the last quarter are -0.88 USD per share, whereas the estimation was -0.92 USD resulting in a +4.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alumis revenue for the last year?▼
Alumis revenue for the last year amounts to 0 USD.
What is Alumis net income for the last year?▼
ALMS.BOATS net income for the last year is -588.47M USD.